# First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07355205/  
OnCo record `nct07355205` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ipilimumab, nivolumab and nogapendekin alfa inbakicept in lung cancer, run by Washington University School of Medicine, now recruiting.

## Summary

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07355205 by Washington University School of Medicine, with a registry enrolment figure of 26 participants, started 2026-07-07 and due to reach its primary completion in 2032-07-31. Interventions recorded: Ipilimumab; Nivolumab; Nogapendekin alfa inbakicept. Conditions listed: Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent. Primary outcome: Progression-free survival (PFS) (Phase Ib acceptable dose participants and Phase II participants); Incidence of dose-limiting toxicities (DLTs) (Phase Ib participants). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed, previously untreated or recurrent metastatic NSCLC". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: FLINN
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07355205
- Phase: 1/2
- Setting: A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)
- Sponsor: Washington University School of Medicine
- Enrolled: 26

## Sources

- ClinicalTrials.gov NCT07355205: https://clinicaltrials.gov/study/NCT07355205

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Nogapendekin alfa inbakicept](https://onco.cc/drugs/nogapendekin-alfa/)
- companies: [ImmunityBio](https://onco.cc/companies/immunitybio/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07355205.json